6th International Symposium on New Quinolones
Transcript of 6th International Symposium on New Quinolones
6th International Symposium onNew Quinolones
Proceedings of the 6th International Symposium on New Quinolones,Denver, Colorado, USA, November 15-17, 1998
Organizing CommitteeEthan Rubinstein (Co-Chairman)Claude Carbon (Co-Chairman)
Dieter AdamRobert C. Moellering Jr
Francis A. Waldvogel
Editorial development by Adis International Limited
This supplement is a cooperative publishing venture of Adis International Limitedand the 6th ISNQ Organizing Committee
Copyright: © 1999 Adis International Limited. All rights reserved throughout the world and in all languages. No part of this publicationmay be reproduced, transmitted or stored in any form or by any means either mechanical or electronic, includingphotocopying, recording or through an information storage and retrieval system, without the written permission of the copyrightholder.
Drugs is indexed in Index Medicus, Medline, EMBASE/Excerpta Medica, Current Contents/Clinical Medicine, Current Contents/LifeSciences, B10SIf> Database, International Pharmaceutical Abstracts (IPA) and CABS. Individual articles are available through theADONIS document delivery service and on-line via the World Wide Web through BioMedNet. Further details are available from thepublisher.
Vol. 58, Supplement 2,1999
Contents
List of Contributors xv-xvi
Foreword xvii
ORAL PRESENTATIONS
The Future of the Quinolones 1-5VTAndriole
Mode of Action of Fluoroquinolones 6-10DC Hooper
Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998 11-18LJVPiddock
Activity of Quinolones Against Mycobacteria 19-22MR Jacobs
Activity of Newer Fluoroquinolones In Vitro Against 23-28Gram-Positive BacteriaGM Eliopoulos
Pharmacokinetics and Pharmacodynamics of 29-36Fluoroquinolones/ Turnidge
Toxicity of Quinolones 37-42R Stahlmann,HLode
Fluoroquinolones in Paediatrics 43-48HS Jafri, GH McCracken Jr
Quinolones in the Aged 49-51LE Nicolle
Quinolones in the Treatment of Typhoid Fever 52-54HEAkalin
Quinolone Use in the Developing World: State of the Art 55-59TE Tupasi
Quinolone Activity Against Anaerobes 60-64PC Appelbaum
Effect of Quinolones on Intestinal Ecology 65-70C Edlund, CE Nord
Cost -Effectiveness of Quinolones in Hospitals and the Community 71-77PDavey
Activity of Quinolones Against Chlamydia pneumoniae 78-81MR Hammerschlag
Contents
Fluoroquinolone Treatment of Skin and Skin Structure Infections 82-84AW Karchmer
Use of Quinolones in Osteomyelitis and Infected 85-91Orthopaedic ProsthesisDP Lew, FA Waldvogel
Quinolones in Sexually Transmitted Diseases: State of the Art 92-95GL Ridgway
The Quinolones and Renal Infection 96-98A Ronald
Newer Quinolones in the Long Term Prophylaxis of Recurrent 99-102Urinary Tract Infections (UTI)S Krcmery, f Hromec, M Tvrdikova, M Hassan, D Gulla
Outcome of Antibiotic Therapy with Ciprofloxacin in Chronic 103-106Bacterial ProstatitisW Weidner, M Ludwig, E Brdhler, HG Schiefer
POSTER PRESENTATIONS
Activity of Quinolones Against Anaerobes and Other Pathogens
Antimicrobial Activity of Gatifloxacin Against Campylobacter jejuni 107-109and Anaerobic BacteriaME Erwin, RN Jones, MS Barrett, MA Pfaller, CL Hayward,GVDoem
Antianaerobic Activity of Grepafloxacin Compared with Ofloxacin, 110-112Ciprofloxacin, Clindamycin, Metronidazole and 5 p-LactamsL Dubreuil, E Singer, MF Odou, F Leblanc
Antianaerobic Activity of Gatifloxacin 113-116LM Ednie, MR Jacobs, PC Appelbaum
Resistance of Quinolones
Grepafloxacin vs Pneumococci Resistant to Fluoroquinolones 117-118by a Putative Efflux MechanismNPBremvald, MJ Gill, R Wise
Mutations to Quinolone Resistance in Pseudomonas aeruginosa 119-120and Enterococcus faeciumS Jalal, N El Amin, N Gotoh, B Wretlind
Activity of Trovafloxacin Against Topoisomerases and GyrA/GrlA 121-122Mutants of Staphylococcus aureusTD Gootz, RPZaniewski, SL Haskell, FS Kaczmarek, AE MauriceOfloxacin Selects First-Step ParC Mutations in Mycoplasma hominis 123-124Whereas Sparfloxacin Selects for First-Step GyrA MutationsGE Kenny, PA Young, FD Cartwright, KE Sjostrom, WM Huang
Contents
Fluoroquinolone Resistance Mutations in the DNA 125-127Topoisomerase II Genes of Viridans Group StreptococciClinical IsolatesD Balas, I Gonzalez, M Georgiou, F Alcaide, J Linares AG De La Campa
Nosocomial Superinfections with Gram-Negative Pathogens 128-129and Quinolone Resistance after Treatment with Ciprofloxacinvs OfloxacinY Canneli, MH Samore
Resistant Mutants of Staphylococcus aureus with Ofloxacin 130-131in Comparison with CiprofloxacinY Rio, FJurin, J DidionMechanisms and Frequency of Resistance to Moxifloxacin 132-133in Comparison with Ciprofloxacin in Staphylococcus aureusD Ince, R Aras, DC Hooper
Mechanisms and Frequency of Resistance to Gatifloxacin 134-135in Comparison with Ciprofloxacin in Staphylococcus aureusD Ince, R Aras, DC Hooper
Mutational Resistance to Quinolones in Staphylococci: 136-137Trovafloxacin vs CiprofloxacinKS Thomson, ES Moland, CC Sanders
Comparative In Vitro Activity of Grepafloxacin Against Selected 138-140Mutants and Clinical IsolatesCJ Soussy, F Leblanc
Antibacterial Activity of Quinolones
Synergistic Activity of Trovafloxacin with Other Agents 141-143MA Visalli, S Bajaksouzian, MR Jacobs, PC Appelbaum
Antimicrobial Activity of Moxifloxacin and Levofloxacin 144-145Photodegradation ProductsCM Tobin, J Sunderland, APMacGowan, AJ Hedges, LO White
Comparative Postantibiotic Effect of Sitafloxacin and Trovafloxacin 146-148on Methicillin-Resistant Staphylococcus aureusEJ Giamarellos-Bourboulis, P Grecka, H Sambatakou, Z Chryssouli,H Giamarellou
Synergistic In Vitro Activity of Clinafloxacin 149-150MB Perri, MJ Zervos
Comparative Antibiotic Activity Versus Vancomycin 151-153Intermediate-Susceptible Staphylococcus aureusMD Huband, MA Cohen, JW Gage, SR VanderRoest
Activity of Trovafloxacin Against Micro-Organisms Isolated from 154-155Diabetic Patients with Lower Extremity InfectionsK Weiss, M Laverdiere, C Restieri, L Poirier
Moxifloxacin: Comparative Inhibitory Bactericidal Activity Against 156-159Susceptible and Multidrug-Resistant Gram-Positive BacteriaA Speciale, G Aleo, K La Ferla, R Musumeci, F Caccamo, G Nicoletti
Contents
Antistaphylococcal Activity of Moxifloxacin 160-161A Dalhoff
Antimicrobial Activity of Gatifloxacin Tested Against 1676 162-163Gram-Positive Cocci Resistant to Ciprofloxacin: A MulticentreOrganism Sample from North and Latin AmericaRN Jones, MA Pfalter, GV Doern, M Beach, SENTRY Participants Group
Antistreptococcal Activity of Gatifloxacin 164-165RN Jones, DM Johnson, ME Erwin, ML Beach, DJ Biedenbach
Antibacterial Activity of Gatifloxacin in Obstetrics and Gynaecology 166-168K Izumi, H Mikamo, K Kawazoe, T Tamaya
In Vitro Antibacterial Activities of Gatifloxacin (AM-1155) Against 169-170Clinical Pathogens Recently Isolated from Various InfectionsY Tsurutnaki, HManda, M Takei, Y Oomori
Ofloxacin Photodegradation Products Possess Antimicrobial Activity 171-172J Sunderland, CM Tobin, LO White, AP MacGowan, AJ Hedges
Antimicrobial Spectrum of Gatifloxacin in the SENTRY Program 173-175RN Jones, MA Pfaller, GV Doern, M Beach, SENTRY Participant Group
Gatifloxacin Susceptibility Testing Interpretive Criteria and Quality 176-177Control Guidelines for Dilution and Disk Diffusion MethodsKC Kugler, RN Jones, DJ Biedenbach, ME Erwin, MA Pfaller, GV Doern,Quality Control Study Group
In Vitro Antimicrobial Activity of Gatifloxacin Against N. gonorrhoeae 178-179and H. influenzaeDJ Biedenbach, RN Jones, ML Beach, MS Barrett, DM Johnson, MA Pfaller,GV DoernAntimicrobial Activity of Gatifloxacin Against Stenotrophomonas 180-181maltophilia and Burkholderia spp.DJ Biedenbach, RN Jones, SA Marshall, DM Johnson, MAT CrocoActivity of Moxifloxacin Against Klebsiella pneumoniae 182-183A Dalhoff
Serum Bactericidal Activity of Moxifloxacin 184-185A Dalhoff, H Stass, S Obertegger
Current Activity of Ciprofloxacin Against Gram-Negative Bacilli 186-187in the United StatesC Thornsberry, MK Marsilio, ME Jones, KM Tomfohrde, BH Heller,G Piazza, DF Sahm
Comparison of In Vitro Activity of Trovafloxacin, Ciprofloxacin and 188-189Ceftazidime on Clinical IsolatesB Ongen, A Kaygusuz, L Oksiiz, K ToreciComparative Activity of 7 Quinolones Against Non-Glucose 190-192Fermenting Gram-Negative Bacilli Isolated from Cancer PatientsM Balakrishnan, HMago, B LeBlanc, KV1 Rolston
Susceptibility of Anaerobic Gram-Negative Rods to Trovafloxacin 193-194M Litterio, L Castello, A Rollet, A Di Martino, G Greco, L FernandezCanigia, MI Fernandez, S Predari, H Bianchini
Contents
Comparative In Vitro Activity of Trovafloxacin Against 195-199Gram-Positive and Gram-Negative Clinical Isolates from ArgentinaA Sucari, D Stepanik, JM Casellas, G Tome, L Clara, M Marin, A Rossi,M Galas, J Smayevsky, L Dufranc, H Lorenzo, L de Vedia, H Lopez
In Vitro Activity of Trovafloxacin, Ciprofloxacin, Azithromycin, 200-202Roxithromycin and Clarithromycin Against 355 Clinical Isolateswith Different Resistance PatternsJM Casellas, G Tome, M Gilardoni, G Pagniez, S Ivanovic
Trovafloxacin: In Vitro Activity and Comparison with Other 203-206Antibacterial Agents: WHONET-Resisnet Program, 1998A Rossi, M Tokumoto, M Galas, L Guelfand, H Lopardo,WHONET-Argentina Collaborative Group
Activity of Trovafloxacin Against P. aeruginosa, 207-208Methicillin-Resistant S. aureus and PneumococciLM Kelly, MR Jacobs, PC Appelbaum
Susceptibility of Pseudomonas aeruginosa Isolates from Cystic 209-210Fibrosis Patients to CiprofloxacinA Bauernfeind, R Jungwirth, F Ratjen
Susceptibility of Pseudomonas aeruginosa to Levofloxacin and 211-213Trovafloxacin Based on MICs for Ciprofloxacin and OfloxacinKB Waites
Susceptibility of Stenotrophomonas maltophilia to Moxifloxacin, 214-216Trovafloxacin, Ofloxacin and CiprofloxacinHB Hawley, HM Polenakovik, JS Czachor, SS Mueller
Clinafloxacin Antibacterial Activity 217-221LM Ednie, MR Jacobs, PC Appelbaum
Pharmacokinetic Features of Fluoroquinolones
Single Dose Pharmacokinetics of the R~ and S-Enantiomers of 222-224Gatifloxacin in VolunteersH-J Stahlberg, K Goehler, M Guillaume, AMignot
Basic Pharmacokinetics of Moxifloxacin 225-226H Stass, D Kubitza
Absorption and Bioavailability of Moxifloxacin 227-228HStass
Distribution and Tissue Penetration of Moxifloxacin 229-230HStass
Metabolism and Excretion of Moxifloxacin 231-232H Stass
Pharmacokinetics of Moxifloxacin in Special Populations 233-234H Stass, 7 Lettieri
Interaction Profile of Moxifloxacin 235-236H Stass, D Kubitza
Contents
Advances in Bioanalytical Methodology Used to Characterise 237-238Clinical Pharmacokinetics of MoxifloxacinJ-G Moller, H Stass, W Muck
Determination of Moxifloxacin by HPLC and Bioassay: Practicality 239-241and LimitationsA Dalhoff, H Stass
Impact of Neutropenia on Tissue Penetration of Moxifloxacin and 242-245Sparfloxacin in Infected MiceR Garraffo, C Roptin, A Boudjadja
Effect of Age on Clinafloxacin Pharmacokinetics in Healthy 246-247VolunteersEJ Randinitis, R Abel, NJ Bron, NJ Hounslow, G Rausch, AB Vassos
Effect of Clinafloxacin on the Pharmacokinetics of Theophylline 248-249and CaffeineEJ Randinitis, JR Koup, G Rausch, AB Vassos
Clinafloxacin Pharmacokinetics in Renal Patients 250-251EJ Randinitis, JR Koup, G Rausch, NJ Bron, NJ Hounslow, AB Vassos,AJ Sedman
Pharmacokinetics of Oral and Intravenous Clinafloxacin 252-253EJ Randinitis, J Brodfuehrer, AB Vassos
Drug Interaction Studies with Clinafloxacin and Probenecid, 254-255Cimetidine, Phenytoin and WarfarinEJ Randinitis, JR Koup, NJ Bron, NJ Hounslow, G Rausch, R Abel,AB Vassos, AJ Sedman
Effects of Food and Antacid on the Pharmacokinetics of 256-257ClinafloxacinC Alvey, EJ Randinitis, G Rausch, AB Vassos
In Vitro Pharmacodynamic and Pharmacokinetic Aspects of 258-259THP-1 Human Monocyte Uptake, Distribution and Efflux of14C-Grepafloxacin under Different ConditionsMA Dietrich, JD Butts, PAlford, TJ Ives, IH Hall
Fluoroquinolones in Miscellaneous Severe Infections
Clinafloxacin in Serious Infections Caused by Multiply Resistant 260-262PathogensKJ Tack, I Eiseman, M Zervos
Ciprofloxacin in the Treatment of Nosocomial Meningitis 263-265in Neonates and Infants: A Report of 12 Cases7 Filka, J Uher, H Kurak, T Sagdt, J Tuharsky, I Novak, T Urbanova,K Kralinsky, S Dluholucky, T Krcmery ova, V Krcmery Jr
Bacteraemia and Fungaemia During Ofloxacin Prophylaxis in 266-268Cancer PatientsV Krcmery Jr, J Trupl, A Demitrovicova, E Kukuckova,M Studena, F Mateicka
Pharmacodynamics of Trovafloxacin vs Ceftriaxone in 269-270Streptococcus pneumoniaePD Lister, CC Sanders
Contents
Use of Intravenous Ciprofloxacin in a Canadian Medical Centre 271-272JA Karlowsky, AS Gin, R Cooper, DJ Hoban, GG Zhanel
Treatment of Pneumonia with Fluoroquinolones
A Critical Pathway for the Treatment of Community-Acquired 273-275PneumoniaTJ Marrie, CY Lau, SL Wheeler, CJ Wong, MK Vandervoort, BG Feagan,capitaL Study Investigators
The Microbiological Eradication Rate of First-Line Antibiotic 276-277Treatment is a Key Cost Driver in the Treatment of Acute BacterialExacerbations of Chronic BronchitisLF Lacey, T Volmer, AM Harris
The Clinical Failure Rate of First-Line Antibiotic Treatment is 278-279the Key Cost Driver in Community-Acquired Lower RespiratoryTract InfectionsH77 van Barlingen, T Volmer, LF Lacey
Efficacy of Gatifloxacin in Pneumococcal Respiratory Infection 280-281R Soejima, A Saito
Ofloxacin Once Daily Versus Twice Daily in Community-Acquired 282-283PneumoniaV Krcmery Jr on behalf of the Slovak GP Study Group
Fluoroquinolones in Surgical Infections
Oral Trovafloxacin Versus Intravenous Cefoxitin in Elective 284-285HysterectomyDR Luke, Trovafloxacin Surgical Prophylaxis Study Group
Alatrofloxacin Versus Cefotetan in Prophylaxis of Colorectal 286-287SurgeryDR Luke, Trovafloxacin Surgical Prophylaxis Study Group
Comparison of the Efficacy and Safety of Once-Daily Oral 288-290Trovafloxacin and 3-Times-Daily Amoxicillin/Clavulanic Acid forthe Treatment of Complicated Skin and Soft-Tissue InfectionsR Daniel, Trovafloxacin Study Group 'Once-Daily Oral Trovafloxacin in the Treatment of Diabetic Foot 291-292Infections: Results of an Open-Label, Noncomparative,Multicentre TrialR Daniel, Trovafloxacin Study Group
Trovafloxacin Once Daily vs Flucloxacillin Four Times Daily in the 293-294Treatment of Uncomplicated Skin and Skin-Structure InfectionsR Daniel, Trovafloxacin Study Group
Comparison of Intravenous to Oral Trovafloxacin vs Intravenous 295-297Imipenem/Cilastatin to Oral Amoxicillin/Clavulanic Acid inComplicated Intra-Abdominal InfectionsDR Luke, Trovafloxacin Intra-Abdominal Infection Study Group
Contents
Failure of Alatrofloxacin in Patients with Deep Surgical Infection 298-300V Gandhi, K Patel, EM Sordillo
Trovafloxacin in Respiratory Tract Infections
Oral Trovafloxacin vs Oral Cefuroxime ± Erythromycin 301-303in Community-Acquired Pneumonia7 Peterson, Trovafloxacin Study Group
Trovafloxacin vs High Dose Amoxicillin in the Treatment of 304-305Community-Acquired Bacterial Pneumonia: Results of aMulticentre, Double-Blind StudyR Daniel, Trovafloxacin Study Group
Trovafloxacin vs Amoxicillin/Clavulanic Acid in the Treatment of 306-308Acute Exacerbations of Chronic Obstructive BronchitisR Daniel, Trovafloxacin Study Group
IV-to-Oral Switch Therapy with Trovafloxacin Compared with 309-311IV Ceftazidime/Oral Ciprofloxacin in the Treatment ofNosocomial PneumoniaHP Bassaris, D Williams Hopkins, R Daniel, Trovafloxacin Study Group
Trovafloxacin vs Clarithromycin in Patients with Ambulatory 312-314Community-Acquired PneumoniaD Williams Hopkins, Trovafloxacin Study GroupTrovafloxacin vs Amoxicillin in the Oral Treatment of Acute Bacterial 315-317Exacerbations of Chronic BronchitisR Daniel, Trovafloxacin Study Group
Trovafloxacin vs Ceftriaxone/Cefpodoxime ± Erythromycin in 318-319Hospitalised Community-Acquired PneumoniaD Williams Hopkins, R Daniel, Trovafloxacin Study Group
Oral Trovafloxacin Compared with Amoxicillin 320-322(plus Optional Erythromycin) for the Treatment ofMild to Moderate Community-Acquired PneumoniaR Daniel, Trovafloxacin Study Group
Trovafloxacin vs Ciprofloxacin ± Clindamycin/Metronidazole in 323-325Patients with Nosocomial PneumoniaD Williams Hopkins, R Daniel, Trovafloxacin Study Group
Fluoroquinolones in Otitis and Sinusitis
Oral Levofloxacin Compared with Clarithromycin in Acute Sinusitis 326-327B Lasko, CYLau, RJ Anstey, C St-Pierre, AY Martel, F Diaz-Mitoma,Canadian Collaborative Sinusitis Study Group
Ciprofloxacin and Cefuroxime Axetil in Acute Community-Acquired 328-329RhinosinusitisM Weis, K Hendrick, K Gravelle, G Tillotson, Rhinosinusitis InvestigationGroup
Contents
Fluoroquinolones in Urinary Tract Infections
Are the Fluoroquinolones Comparable in the Treatment of Urinary 330-334Tract Infections?KG Naber
Effects of Ciprofloxacin in Urinary Tract Infections Using Different 335-338Dose RegimensK Janicki
Efficacy and Safety of Ofloxacin in Ureaplasma Infections of the 339-340Upper Urinary TractJD Dimitrakov, DJ Dimitrakov, G Rawadi
Ciprofloxacin in the Treatment of Chronic Bacterial Prostatitis 341-343KG Naber, J Focht, WBusch, German Prostatitis Study Group
Fluoroquinolone Activity Against Respiratory Pathogens
Activity of Moxifloxacin Against Moraxella catarrhalis 344-345and AtypicalsA Dalhoff
The Activity of Fluoroquinolones and Other Antimicrobial Agents 346-348Against Streptococcus pneumoniae, Haemophilus influenzae, andMoraxella catarrhalisC Thornsberry, P Ogilvie, HPHolley, ML Hickey, ME Jones, IA Critchley,DF Sahm
Activity of Moxifloxacin Against H. influenzae and H. parainfluenzae 349-350ADalhoff
Antipneumoccal Activity of Moxifloxacin 351-353A Dalhoff '
Inhibition of Pneumococcal Topoisomerases by Sitafloxacin 354-355I Morrissey, JT George
Serum Bactericidal Activity of Trovafloxacin Against 356-357Drug-Resistant Respiratory PathogensGE Stein
Grepafloxacin Activity Against 3000 Canadian Respiratory 358-360Tract PathogensDJ Hoban, GG Zhanel, L Palatnick, B Weshnoweski, L Vercaigne,JA Karlowsky
Surveillance of Antimicrobial Resistance among Respiratory Tract 361-363Pathogens in the United States, 1997 to 1998C Thornsberry, ML Hickey, J Kahn, YMauriz, DF Sahm
International Surveillance of Susceptibility to Levofloxacin and 364-365Other Agents among Respiratory PathogensC Thornsberry, ML Hickey, ME Jones, IA Critchley, GP Park, DF Sahm
Levofloxacin and Clarithromycin Antipneumococcal Activity 366-368CL Clark, MR Jacobs, PC Appelbaum
Contents
Antipneumococcal Activity of Gatifloxacin by Time-Kill 369-371MethodologyG Lin, MR Jacobs, PC Appelbaum
Antipneumococcal Activity of Gatifloxacin by Agar Dilution MIC 372-373DB Hoellman, MR Jacobs, PC Appelbaum
Susceptibility of Respiratory Pathogens to Grepafloxacin 374-375R Cisterna, M Gobernado, JA Garcia Rodriguez
Bactericidal Activity of Grepafloxacin Against Respiratory 376-377PathogensF Daschner, U Frank, K Huber
Postantibiotic Effect of Levofloxacin Against Pneumococci 378-380SK Spangler, G Lin, MR Jacobs, PC Appelbaum
MICs for Streptococcus pneumoniae with Reduced Penicillin 381-382SusceptibilityVA Luna, MC Roberts
Development of High Level Quinolone Resistance in Streptococcus 383-384pneumoniae During Sequential Quinolone TherapyB Suh, B Lorber, S Gelone, AL Truant, TD Gootz
Safety and Side Effects of Fluoroquinolones
Chondrotoxicity and Target Tissue Kinetics of Ofloxacin 385-387in Immature Rats after Multiple DosesR Schwabe, E Lozo, I Baumann-Wilschke, R Stahlmann
Chondrotoxicity of Ciprofloxacin in Immature Beagle Dogs 388-389R Stahlmann, S Kiihner, M Shakibaei, R Schwabe, D van Sickle
Effects of Ofloxacin on the Ultrastructure of Achilles Tendon in Rats 390-392M Shakibaei, K Pfister, R Schwabe, R Stahlmann
Supplementation with Magnesium and Tocopherol Diminishes 393-394Quinolone-Induced Chondrotoxicity in Immature RatsR Stahlmann, R Schwabe, K Pfister, E Lozo, M Shakibaei, J Vormann
Clinical Safety Profile of Grepafloxacin 395-396H Lode, F Vogel, W Elies
Phototoxic Potential of Gatifloxacin, a New Fluoroquinolone 397-399Antimicrobial7 Ferguson, J McEwen, K Gohler, A Mignot, D Watson
Activity of Fluoroquinolones Against Mycobacteria andIntracellular Pathogens
Comparative Antimycobacterial Activity of BAY 12-8039 and 400-401GatifloxacinH Saito
Contents
Fluoroquinolones in the Treatment of Atypical Mycobacterial 402-403Infections in AIDSM Bassetti, C Bussolino, M Cruciani, A Collida, V Del Bono, A Di Biagio,G Mazzarello, E Pontali, E Mantero, G Gatti, D Bassetti
In Vitro Activity of Grepafloxacin Against Chlamydia trachomatis 404-405F Poutiers, S Dessus-Babus, F Leblanc, C Bebear, B de Barbeyrac
Susceptibility of Mycoplasma hominis to Moxifloxacin by E-Test and 406-407Agar DilutionKB Waites, KC Canupp, GE Kenny
Infection Models
Therapeutic Effects of Sitafloxacin in Rat Uterine Endometritis 408-409H Mikanto, K Kawazoe, K Izumi, T Tamaya
Pharmacodynamics of Trovafloxacin and Ciprofloxacin Against 410-411Ciprofloxacin-Resistant Viridans StreptococciPD Lister, CC Sanders
Therapeutic Efficacy of Sitafloxacin Against Pseudomonas aeruginosa 412-414in a Rat Model of Urinary Tract InfectionY Kurosaka, Y Ishida, E Yamamura, T Otani, H Kumon
Quinolone Activity Against Respiratory Pathogens 415-416B Wiedemann
Pharmacodynamic Activity of Levofloxacin in an In Vitro Model 417-419Against Gram-Positive and Gram-Negative BacteriaB Wiedemann, E Pfeil